SteerX’s Post

𝐀𝐟𝐭𝐞𝐫 𝐭𝐡𝐞 𝐬𝐭𝐨𝐫𝐦, 𝐈𝐧𝐝𝐢𝐚’𝐬 𝐡𝐞𝐚𝐥𝐭𝐡𝐭𝐞𝐜𝐡 𝐢𝐬 𝐬𝐞𝐭 𝐟𝐨𝐫 𝐛𝐫𝐢𝐠𝐡𝐭𝐞𝐫 𝐝𝐚𝐲𝐬 !📈 India’s #healthtech sector has often been overshadowed by giants like e-commerce and fintech. Healthtech #startups have raised $7 billion across 886 deals since 2014 but still trail the $63 billion raised by other sectors. Companies like Tata 1mg, Innovaccer, PharmEasy, Molbio Diagnostics, and Pristyn Care are working to change the narrative. 🩺 Challenges are real PharmEasy faced a 90% valuation drop, while Kenko Health and ConnectedH had to close. Yet, 2024 offers a glimmer of hope, with healthtech securing $460 million in H1 a 2.8x jump from 2023. With consumer trust, investor backing, and targeted #innovation, healthtech could emerge as a crucial player in India's digital landscape 🌍. 🔗Read More - https://lnkd.in/dX6fYqGk 🖊️Written By - Dr. Aishwarya S 🌐Stay Informed with our Latest Stories – https://lnkd.in/gMUPB2Zp #HealthtechRevival #Innovation #StartupEcosystem #DigitalHealth #Telemedicine #HealthcareInnovation #HealthTechIndia #FutureOfHealthcare #IndianStartups #TechForGood #HealthTechUnicorns

Orange Health Labs Secures $12M Funding Led by Amazon Smbhav Venture Fund 🚀🧪 Founded in 2020 by Tarun Bhambra and Dhruv Gupta - Orange Health, Bengaluru's trailblazing diagnostic-tech startup, has raised $12 million in its latest funding round. The company has transformed at-home diagnostics by delivering results for over 2,000 tests in just 60 minutes ⏱️, setting a new benchmark in rapid healthcare services. Why Orange Health Matters 🩺✨ 🚑 Convenience Meets Reliability: With a stellar 4.9/5 rating ⭐️, Orange Health is redefining healthcare access, combining online and offline capabilities to offer dependable diagnostics right at your doorstep 🏠. 💡 Catalyzing Innovation: This funding will fuel advancements in diagnostic technology, team expansion, and product development, further driving its patient-first mission. ⏰ A Boon for Real-Time Care: Rapid testing solutions ensure early detection and timely treatment, addressing a critical need in India's healthcare ecosystem. 📈 Backing from Amazon: With the support of the Amazon Smbhav Venture Fund, Orange Health is poised for significant growth in the booming health-tech sector. This milestone reinforces the transformative role of diagnostics in patient care, positioning Orange Health as a key player in India’s healthcare evolution. 🌟 #OrangeHealth #HealthTech #Diagnostics #StartupFunding #India #News #IndiaStartups #HealthcareInnovation #BengaluruStartups #HealthCare #Medical #Startup #RapidDiagnostics #IndiaHealthcare #Orange #Tech #Hypes Start Big, Start Here.

🦄 Another Indian Unicorn bites the dust recently. And it’s PharmEasy- the online Pharmacy- which has raised $210mn (Rs 1804 crore) at a 90% Valuation cut - Their last Series F Round Valuation was $5.6 Billion on October 2021 - Current $710mn Valuation is almost same as their Series D round ($700mn Valuation) on November 2019 According to a report by Entrackr: - Ranjan Pai’s Manipal Education and Medical Group (MEMG family office) led the round with $93mn while Prosus, Temasek, and 360 One Portfolios pumped in $26mn, $22mn, and $23mn, respectively.  - CDPQ Private Equity, WSSS Investments, Goldman Sachs, and Evolution Debt Capital cumulatively participated with $46mn in the new investment. Earlier PharmEasy paid $927M for Thyrocare in June 2021 and $144M for Aknamed, a supply chain management platform for hospitals and medical manufacturers, in Sept 2021. Here is a brief of PharmEasy Valuation by Round: - Series C-II- $150mn (Sept 2018) - Series D- $700mn (Nov 2019) - Merger- $1.2bn (Aug 2020) - Series E- $1.5bn (Feb 2021) - Unattributed VC- $1.8bn (June 2021) - Secondary Market- $5.6bn (Oct 2021) - Series G-II- $710mn (Apr 2024) It’s quite obvious that this new funding will result in the promoters being diluted way more than they ever hoped to be but the best part is that the company survived and might have another shot at success. Other notable players from India in this Online Pharmacy space are 1mg acquired by Tata and Netmeds acquired by Reliance Industries. IC: CB Insights ~~~~~ ♻️ Found this helpful? Repost it so your network can learn from it, too. And follow me, Fazlur Shah for more content like this. #startups #entrepreneurship #venturecapital #investing

HealthKart, India’s leading healthtech startup, has raised $153 million (INR 1,291 crore) in its latest funding round, led by ChrysCapital and Motilal Oswal Alternates (MOA). The round also saw participation from A91 Partners, boosting the company's ability to further its expansion plans. In a significant move, HealthKart has also announced an INR 55 crore employee ESOP buyback, benefiting both current and former employees, reflecting its commitment to rewarding and retaining talent. Founded by Sameer Maheshwari and Prashant Tandon, HealthKart continues to lead India’s largest online nutrition marketplace, with a growth trajectory that has seen its revenue soar by 70%, reaching INR 832.4 crore in FY23. The company plans to use the fresh funding to strengthen its key brands—MuscleBlaze, HK Vitals, and TrueBasics—while also expanding its presence globally. #healthkart #sportsnutrition #healthtech #nutritionmarketplace #muscleblaze #hkvitals #startupsuccess

HealthTech startup Practo turned adjusted EBITDA positive in Q4 FY24 and is set to maintain this momentum in FY25. The company saw a 90% reduction in adjusted EBITDA loss to INR 17 Cr in FY24, driven by a 68% CAGR and increased contribution margins to 40%. Revenue grew by 22%, reaching INR 242 Cr. #EmergingTiger #Healthtech #StartupSuccess #EBITDA #RevenueGrowth #OperationalEfficiency #FinancialPerformance

Pharmeasy, a prominent player in India's health-tech sector, has seen its valuation dip from $1 billion to $500 million. The drastic reduction comes as the startup faces hurdles in raising funds amid stiff competition from rivals like Apollo Pharmacy. Market experts cite operational inefficiencies and a saturated market as contributing factors. Despite these challenges, Pharmeasy is restructuring its operations and optimizing costs to attract potential investors. #Pharmeasy #HealthTech #IndiaStartups #StartupValuation #FundingNews

#Update This week witnessed substantial investment in promising Indian startups. Healthcare: Innovaccer secured USD 275M to enhance its digital health platform, while Botanic Healthcare raised USD 30M for its botanical extracts. Fintech: OYO received USD 65M, Infinity Fincorp Solutions Private Limited secured USD 35M to expand financial access to micro-entrepreneurs, and GrayQuest raised USD 9.3M for its education-focused payment platform. Other Sectors: HARSORIA HEALTHCARE PVT. LTD. (medical devices) raised USD 20M, and Vehant Technologies (AI-driven security) garnered USD 9M. These funding rounds demonstrate strong investor confidence in India's burgeoning startup ecosystem, fueling innovation across key sectors. Read the story: https://ow.ly/XwSJ50UF4ql #IndianStartups #FintechIndia #HealthcareInnovation #StartupFunding #InvestmentNews #StartupEcosystem #TechInvestment #Entrepreneurship #VentureCapital #Innovation

Why 2024 is the Best Time to Do a Health-Tech Startup? Here, I discuss various key factors that make 2024 an optimal year for starting a health-tech venture, such as changing consumer behaviour, supportive government initiatives in India, rising medical costs that drive demand for insurance and cost-saving solutions, the advantages of remote work in accessing global talent, a focus on early-stage funding, and the use of advanced AI tools to boost business efficiency. Would love to hear your thoughts. #healthcare #startup #healthtech #VC #funding #India #Startupindia

$456M: PharmEasy's New Valuation After Investor Takes a Hit. The Changing Landscape of Indian Startups   India's startup ecosystem has witnessed dynamic shifts in recent years, with health tech emerging as a focal point. Among the prominent names, PharmEasy has stood out, revolutionizing how people access medicines and healthcare services. However, a recent event has cast a shadow on its growth narrative: an investor write-down that now pegs PharmEasy's valuation at $456M. This development has sent ripples through the health tech industry, stirring questions about its future trajectory. The $456M valuation comes as a stark contrast to PharmEasy's earlier unicorn status. Once hailed as a game-changer, this adjustment underscores the challenges faced by Indian startups in sustaining their lofty valuations amidst global economic turbulence. Despite this setback, PharmEasy's story is far from over. Understanding the nuances of this development requires a deep dive into its funding journey, market positioning, and the broader health tech trends.     How Did PharmEasy Reach Here? A Funding Timeline   PharmEasy’s journey from inception to becoming a household name in India has been marked by aggressive expansion and substantial funding rounds. Founded in 2015, the company initially aimed to bridge the gap between pharmacies and consumers through a seamless digital platform. Over the years, it attracted significant investor interest, with global and domestic firms pouring capital to fuel its growth. In 2021, PharmEasy reached its peak with a valuation exceeding $5 billion after acquiring Thyrocare, a diagnostic chain. This strategic acquisition was a pivotal moment, as it solidified PharmEasy’s position as a comprehensive healthcare provider. However, the narrative took a turn in 2023, as market realities began to weigh heavily. The latest investor write-down, resulting in a $456M valuation, highlights the challenges of sustaining growth in a capital-intensive industry. A closer look reveals that the company's reliance on external funding and market pressures may have contributed to this recalibration.     The Investor Write-Down: What Does It Mean?   An investor write-down typically signals a reduced expectation of a company’s future profitability or market potential. In PharmEasy's case, this adjustment was driven by multiple factors, including declining market sentiment, financial performance, and macroeconomic headwinds. This $456M valuation represents a significant departure from PharmEasy’s unicorn status, marking a reality check for stakeholders. For investors, it’s a moment of reckoning—an acknowledgment that their earlier bets on health tech startups may not yield the returns once anticipated. For PharmEasy, the write-down is both a challenge and an opportunity to revisit its strategy. https://lnkd.in/dFnnSQNB